×

Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced Diffuse Large B Cell Lymphoma

SHANGHAI, China and CUPERTINO, Calif., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that it would provide a meaningful update on its CD20 Chimeric Antigen Receptor T-cell (CAR-T) Phase IIa trial in Advanced, Refractory or Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) at the upcoming 4th International Conference on Translational Medicine to be held on October 26-28, 2015 in Baltimore, Maryland, USA.

Title: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma: An early Phase IIa trial report
Scientific Program: October 26, 2015 16:15-16:40 EDT
Location: DoubleTree by Hilton Hotel Baltimore - BWI Airport, Chesapeake Hall
Presenter: Yihong Yao, Ph.D., Chief Scientific Officer, Cellular Biomedicine Group

Full details of the presented data will be available on the Company’s website following the presentation.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our GMP facilities in China, consisting of nine independent cell production lines, are designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com

Source:Cellular Biomedicine Group Inc.